PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32333783-8 2020 The effect of 2ME2 treatment on the promoter activity of hSR-BI/CLA-1 was abrogated by treatment with LY294002, a specific inhibitor of phosphatidylinositol 3-kinase, as was the increase in HDL-induced eNOS activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 nitric oxide synthase 3 Homo sapiens 202-206 11961297-7 2002 LY294002 was found to attenuate VEGF-stimulated eNOS expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 48-52 11788791-12 2001 PI-3-kinase inhibitors, Wortmannin and LY294002 inhibited arsenite-induced phosphorylation of AKT and eNOS but had no effect on phosphorylation of p38. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 nitric oxide synthase 3 Homo sapiens 102-106 34666758-9 2021 RESULTS: SC79 induced a ~ twofold induction of p-eNOS and Nrf-2 protein levels blocked by PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 nitric oxide synthase 3 Homo sapiens 49-53 35602302-12 2022 Pretreatment with LY294002 significantly restored iHAX-1-induced decline in PI3K/AKT/mTOR/eNOS phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 nitric oxide synthase 3 Homo sapiens 90-94 34020670-7 2021 LY294002 inhibited the biological function of HUVECs through inhibition of the PI3K/AKT/eNOS pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 88-92 31281371-13 2019 These effects were associated with the increase in p-Akt/Akt and p-eNOS, which could be abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 nitric oxide synthase 3 Homo sapiens 67-71 32103904-13 2020 Importantly, the cytoprotective effect of H2S against HG-induced injury was inhibited by LY294002 (an inhibitor of PI3K/Akt/eNOS signaling pathway). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 nitric oxide synthase 3 Homo sapiens 124-128 31606200-7 2019 Mechanism studies demonstrated that TSH promoted AKT phosphorylation (P<0.05), and that LY294002 inhibited the reduction of eNOS expression by TSH. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 nitric oxide synthase 3 Homo sapiens 124-128 28371277-6 2017 Compared to the blank group, PI3K, Akt and eNOS were down-regulated in the miR-138 mimic and LY294002 groups but were up-regulated in the miR-138 inhibitor group. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 nitric oxide synthase 3 Homo sapiens 43-47 30639474-5 2019 Increased phosphorylated eNOS was significantly inhibited by a PI3K inhibitor LY294002 and elevated ICAM-1expression was partially blocked by the inhibitors of both PI3K and eNOS (L-NAME). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 78-86 nitric oxide synthase 3 Homo sapiens 25-29 30272818-10 2019 These effects were associated by an increase in p-Akt/Akt and p-eNOS, and a decrease in cleaved caspase-3 could be abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 nitric oxide synthase 3 Homo sapiens 64-68 28371277-7 2017 The miR-138 mimic and LY294002 groups showed decreased concentrations of TNF-alpha, IL-6, IL-8 and NO and reduced activities of LDH and eNOS, while opposite trends were observed in the miR-138 inhibitor group. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 nitric oxide synthase 3 Homo sapiens 136-140 25257463-10 2014 BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 nitric oxide synthase 3 Homo sapiens 39-43 27777063-8 2016 Moreover, either LY294002 or TFP abolished the liraglutide-induced upregulation of GTPCH1 and eNOS protein levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 17-25 nitric oxide synthase 3 Homo sapiens 94-98 27378570-10 2016 LY294002 totally abrogated the infarct-limiting effect of GYY4137 and inhibited Akt, eNOS and GSK-3beta phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 85-89 26824621-6 2016 The Danggui Buxue Tang-induced phosphorylation of endothelial nitric oxide synthase and Akt kinase in human umbilical vein endothelial cells were fully blocked by treatment with an endothelial nitric oxide synthase inhibitor (L-NAME), a PI3K/Akt inhibitor (LY294002), and a Ca(2+) chelator (BAPTA-AM). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 257-265 nitric oxide synthase 3 Homo sapiens 50-83 26824621-6 2016 The Danggui Buxue Tang-induced phosphorylation of endothelial nitric oxide synthase and Akt kinase in human umbilical vein endothelial cells were fully blocked by treatment with an endothelial nitric oxide synthase inhibitor (L-NAME), a PI3K/Akt inhibitor (LY294002), and a Ca(2+) chelator (BAPTA-AM). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 257-265 nitric oxide synthase 3 Homo sapiens 181-214 24840719-11 2015 Chemerin can increase eNOS and Akt levels in HUVECs, and these results could be partly blocked by LY294002 and L-NAME. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 nitric oxide synthase 3 Homo sapiens 22-26 27590258-10 2017 In addition, the antiapoptotic effect of PCr enhanced p-Akt/Akt protein ratio, NO synthase (eNOS) activation, NO production and cGMP levels and also was partially suppressed by a PI3K inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 195-203 nitric oxide synthase 3 Homo sapiens 92-96 27463705-8 2016 BA-induced eNOS phosphorylation and NO production was completely blocked by pretreatment with ICI 182,780, and was attenuated by pretreatment with the PI3K inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 182-190 nitric oxide synthase 3 Homo sapiens 11-15 25257463-10 2014 BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 nitric oxide synthase 3 Homo sapiens 87-91 25257463-10 2014 BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 nitric oxide synthase 3 Homo sapiens 87-91 25257463-10 2014 BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 nitric oxide synthase 3 Homo sapiens 87-91 22801313-7 2012 The effect of genistein on phosphorylation eNOS(Ser(1179)) level was also observed in the presence of LY294002 or NSC154020 (PI3K and AKT inhibitors). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 nitric oxide synthase 3 Homo sapiens 43-47 23742697-8 2013 LY294002 (Akt/PI3-K inhibitor) or SB203580 (p38 MAPK inhibitor) abolished the effects of H2 S on eNOS phosphorylation, NO production, cell proliferation and tube formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 97-101 25550859-4 2014 The effect of rhACE2 on phosphorylation eNOS level was also observed in the presence of LY294002 (10 mumol/L) (PI3K/AKT inhibitors). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 nitric oxide synthase 3 Homo sapiens 40-44 25550859-8 2014 After HUVEC was intervened by PI3K/AKT pathway inhibitor LY294002, the expression level of phosphorylated eNOS was significantly lower than that in the rhACE2 30 min treatment group (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 nitric oxide synthase 3 Homo sapiens 106-110 25550859-9 2014 rhACE2 may reduce the activity of Ang II inhibited endothelial cell eNOS, which can be blocked by PI3K/AKT pathway inhibitor LY294002, suggesting PI3K/AKT signaling pathway plays an important role in rhACE2"s promotion of the activity of endothelial cell eNOS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 125-133 nitric oxide synthase 3 Homo sapiens 68-72 25550859-9 2014 rhACE2 may reduce the activity of Ang II inhibited endothelial cell eNOS, which can be blocked by PI3K/AKT pathway inhibitor LY294002, suggesting PI3K/AKT signaling pathway plays an important role in rhACE2"s promotion of the activity of endothelial cell eNOS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 125-133 nitric oxide synthase 3 Homo sapiens 255-259 22801313-9 2012 Furthermore, the expression level of phosphorylation eNOS(Ser(1179)) was significantly lower in PIK3/AKT inhibitors LY294002 and NSC154020 treated cells compared with ox-LDL + genistein treated cells (all P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 nitric oxide synthase 3 Homo sapiens 53-57 19429543-5 2009 The induced eNOS and p-Akt expression was inhibited by LY294002, indicating that the effect of nanocomposites could be attributed to the PI3K pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 nitric oxide synthase 3 Homo sapiens 12-16 21352809-8 2011 The phosphorylation of Akt, PI3K and eNOS were up-regulated by oxLDL, which was attenuated by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 nitric oxide synthase 3 Homo sapiens 37-41 19385062-5 2009 The forskolin-induced Akt/eNOS/NO pathway was completely inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, but not significantly suppressed by PKI. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 121-129 nitric oxide synthase 3 Homo sapiens 26-30 20562903-10 2010 Compared with individual drug treatment, Akt phosphorylation and the ratio of p-eNOS/eNOS were up-regulated in the combination group, and this effect was inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 234-242 nitric oxide synthase 3 Homo sapiens 80-84 20562903-10 2010 Compared with individual drug treatment, Akt phosphorylation and the ratio of p-eNOS/eNOS were up-regulated in the combination group, and this effect was inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 234-242 nitric oxide synthase 3 Homo sapiens 85-89 19577623-5 2009 Both GA-induced NO production and eNOS activation were attenuated by pretreatment of the cells with EGTA, an extracellular Ca(2+) chelator, and BAPTA-AM, an intracellular Ca(2+) chelator, but not by LY 294002, a PI3-kinase/Akt inhibitor, suggesting involvement of Ca(2+). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 199-208 nitric oxide synthase 3 Homo sapiens 34-38 19155632-7 2009 It also caused phosphorylation of Akt and eNOS, which were prevented by MnTMPyP, polyethyleneglycol catalase, PP2, wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 130-138 nitric oxide synthase 3 Homo sapiens 42-46 18578689-5 2008 The phosphorylation of eNOS is Akt-dependent and completely reverted by the phosphatidylinositol-3 kinase (PI-3K) inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 124-132 nitric oxide synthase 3 Homo sapiens 23-27 18409050-7 2008 Pretreatment with phosphatidylinositol 3" kinase (Pl3K) inhibitor LY294002 or eNOS inhibitor NG-nitro-arginine methyl ester (LN or L-NAME) inhibited crocetin effect on p-Akt or eNOS, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 nitric oxide synthase 3 Homo sapiens 177-181 18220263-8 2008 The induced eNOS expression was inhibited by LY294002, indicating that the effect of laser on EC could be attributed to the up-regulation of eNOS expression through PI3K pathway at the cellular and molecular levels as a result of the He-Ne laser. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 nitric oxide synthase 3 Homo sapiens 12-16 18220263-8 2008 The induced eNOS expression was inhibited by LY294002, indicating that the effect of laser on EC could be attributed to the up-regulation of eNOS expression through PI3K pathway at the cellular and molecular levels as a result of the He-Ne laser. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 nitric oxide synthase 3 Homo sapiens 141-145 18007078-5 2007 N(w)-nitro-L- arginine methyl ester (L-NAME, eNOS synthase inhibitor) blocked the rosiglitazone-induced NO formation; LY294002 (a PI3K inhibitor) prevented the NO production; and the phosphorylation of eNOS and PKB was induced by rosiglitazone. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 nitric oxide synthase 3 Homo sapiens 202-206 16764985-6 2006 LY294002, a PI3K-inhibitor, blocked SST-induced p-Akt-Ser473 and partially p-eNOS-Ser617, however, it did not reverse SST-induced NHE attenuation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 77-81 16455784-10 2006 We report that pregnancy adaptation of eNOS activation includes the reduced sensitivity to ERK-mediated attenuation of eNOS activity and enhanced stimulation of eNOS activity through a wortmannin-sensitive, LY294002-insensitive, Akt-independent mechanism. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 207-215 nitric oxide synthase 3 Homo sapiens 39-43 16036314-12 2005 Phosphorylation of eNOS Ser1177 under shear stress was elevated by 20 min, a response that was blocked by PI-3K (phosphatidylinositol 3-kinase) inhibitors wortmannin and LY294002, but not the MEK (MAPK kinase) inhibitor UO126. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 nitric oxide synthase 3 Homo sapiens 19-23 15526284-11 2005 LY294002, a phosphatidylinositol 3 (PI3) kinase inhibitor, inhibited the association of eNOS/Akt and the phosphorylation of eNOS but had no effect on the interaction between eNOS and HSP90 during early hours of exposure. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 88-92 15526284-11 2005 LY294002, a phosphatidylinositol 3 (PI3) kinase inhibitor, inhibited the association of eNOS/Akt and the phosphorylation of eNOS but had no effect on the interaction between eNOS and HSP90 during early hours of exposure. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 124-128 15526284-11 2005 LY294002, a phosphatidylinositol 3 (PI3) kinase inhibitor, inhibited the association of eNOS/Akt and the phosphorylation of eNOS but had no effect on the interaction between eNOS and HSP90 during early hours of exposure. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 nitric oxide synthase 3 Homo sapiens 124-128